Business Context and Reporting Period
This Form 8-K Current Report was filed by 10x Genomics, Inc. on June 18, 2024. The filing reports the appointment of a new member to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation.
Material Changes
The primary material change reported is the appointment of Alan V. Mateo to the Board of Directors as a Class II director, effective immediately. His term expires at the 2027 annual meeting of stockholders or until his successor is elected.
Management Commentary and Compensation
The Board appointed Mr. Mateo based on his senior management experience in the life science industry and commercial leadership background, including roles at Veeva Systems Inc., Medidata Solutions, Inc., and PeopleSoft.
Mr. Mateo's compensation package under the Non-Employee Director Compensation Policy includes:
- An annual cash retainer of $55,000.
- A one-time grant of restricted stock units (RSUs) with a target value of $400,000, granted on July 31, 2024, vesting over three years.
- An annual grant of RSUs with a target value of $215,000, granted at the annual meeting of stockholders, vesting over three years.
- Eligibility for additional annual cash retainers for committee service or chairmanship.
Investor Verification Checklist
- Verify the effective date of Alan V. Mateo's board appointment (June 18, 2024).
- Confirm the vesting schedule for the initial $400,000 RSU grant (starting August 21, 2025).
- Review the Company's Non-Employee Director Compensation Policy for details on committee retainers.
- Check for any potential conflicts of interest given Mr. Mateo's current advisory role at Veeva Systems Inc.